MASP2 and COVID-19: Indications that the coronavirus N protein binds MASP‐2 and the detection of MASP‐2 staining in post‐mortem lung sections from COVID‐19 patients (Magro et al, 2020; preprint: Gao et al, 2020) may support a trial of therapeutic anti‐MASP‐2 antibody (such as narsoplimab (OMS721)) to suppress lectin pathway activation.